Latest action: Read twice and referred to the Committee on Finance.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill to make biosimilar drugs cheaper and easier to access for patients.
The problem
Biosimilar drugs cost too much and patients struggle to afford them. Insurance and pharmacy rules make it hard to get these medications.
The proposal
The bill removes barriers to biosimilar drugs. It aims to lower costs and simplify how patients access these medicines through insurance.
The impact
Patients with serious illnesses benefit from lower drug costs. Insurance companies and pharmaceutical companies face changes to their business models.
Biosimilars are cheaper versions of expensive drugs. Making them easier to access helps patients afford lifesaving treatments. Families spend less money on prescriptions.
When biosimilars compete with brand-name drugs, prices fall. This benefits everyone who takes these medicines. Companies have to compete fairly on price.
Lower drug costs mean less money spent on healthcare overall. Hospitals and insurance plans save money. These savings can help more patients get treatment.
Removing insurance barriers means patients can get prescribed biosimilars faster. Doctors have fewer obstacles when recommending these cheaper drugs.
Pharmaceutical companies earn less money if biosimilars sell more cheaply. This could reduce funding for research into new drugs. Innovation may slow down.
Insurance companies lose control over drug pricing negotiations. They may resist these changes. Regulations could limit their business flexibility.
The bill summary is missing, so we cannot see specific rules. It's unclear how these changes would work in practice. Different states may interpret rules differently.
Cheaper drugs may raise questions about quality and safety. Patients might worry about switching from brand-name to biosimilar drugs.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.